Lyell Immunopharma Inc Revenue per Employee (LYEL), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Lyell Immunopharma Inc   (NASDAQ: LYEL)
 

Lyell Immunopharma Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


Lyell Immunopharma Inc 's Revenue per employee fell on a trailing twelve month basis to $ 168, but the productivity of Lyell Immunopharma Inc 's employees remained above the company average.
Within the Healthcare sector Employees of 560 other companies have achieved higher revenue per employee. While revenue/employee total ranking has improved so far to 3679, from total ranking in previous quarter at 4274. Lyell Immunopharma Inc has 161 employees.


What is Sales per Employee Ratio?






Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LYEL Revenue per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Revenue Change -50 % -71.43 % -45.45 % -55.88 % -38.46 %
Sales per Employee (TTM) $ 168 193 224 255 373
LYEL's Total Ranking # 3679 # 4274 # 3818 # 3847 # 3892
Seq. Revenue Change 100 % -66.67 % -60 % 87.5 % 14.29 %

LYEL Company Profile >> Back to LYEL Efficiency Comparisons >> Compare LYEL Sales per Employee to its Competitors

Revenue per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 202
Healthcare Sector # 561
Overall Market # 3679

Revenue per Employee Statistics
High Average Low
$ 525,981 $ 114,635 $ 168
(Dec 31 2022)   (Jun 30 2026)



Financial Statements
Lyell Immunopharma Inc 's Revenue MRQ $ 0 Millions Visit LYEL's Income Statement
Lyell Immunopharma Inc 's Revenues TTM $ 0 Millions Visit LYEL's aggregate revenue growth
What are LYEL's Sales? Visit LYEL's Sales by Segment


  News about Lyell Immunopharma Inc Revenue per employee

Advanced CAR T-Cell Therapy Efforts Lyell Immunopharma Launches Pivotal Phase 3 Trial and Continues to Innovate in ...

SOUTH SAN FRANCISCO, Calif. In a significant leap forward in the treatment of aggressive large B-cell lymphoma, Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical innovator, has announced the initiation of the PiNACLE - H2H, a Phase 3 head-to-head randomized controlled trial. This groundbreaking study will compare the effectiveness of rondecabtagene autoleucel (ronde-cel), an autologous dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy, against established therapies lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) for patients suffering from relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Transforming Cancer Treatment ParadigmsThe release of these details underscores Lyell’s commitment to advancing next-generation CAR T-cell therapies, aiming to provide improved therapeutic options for cancer patients. Ronde-cel has undergone rigorous development, achieving Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration (FDA). This innovative therapy uniquely targets B cells that express either the CD19 or CD20 antigens or both crafted to enhance treatment efficacy by incorporating higher proportions of naïve and central memory T cells. This targeted approach aims not only for improved complete response rates but also seeks to prolong treatment durability for patients in dire need of new therapies.



Other Ratios
Lyell Immunopharma Inc 's Income per Employee
Employees in Major Pharmaceutical Preparations
Major Pharmaceutical Preparations Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
LYEL's Revenue per Employee versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for LYEL's Competitors
Revenue per Employee for LYEL's Suppliers
Revenue per Employee for LYEL's Customers

You may also want to know
LYEL's Sales Growth Rates LYEL's Pe Price to earnings ratio LYEL's Receivables Turnover Ratio LYEL's Stock Quote
LYEL's Net Income Growth Rates LYEL's Ps Price to Sales ratio LYEL's Sales per Employee LYEL's Asset Turnover Ratio
LYEL's Net Margin LYEL's Pb Price to Book ratio LYEL's Financial Strength Ratios LYEL's Dividend Payout Ratio
Date modified: 2026-09-08T20:47:26+00:00




Companies with similar Revenue per Employee for 12 months ending Jun 30 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Jun 30 2026Number of Employees Jun 30 2026
Lyell Immunopharma Inc   167.70 $ 0.027  Million 161 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.